Novartis and Chai Discovery collaborate on antibody identification

Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies. The partnership is an extension of over 12 months of technical engagement between the two companies. Chai Discovery’s technology uses AI to predict molecular interactions and redesign biomolecules with targeted properties. Credit: Gorodenkoff / Shutterstock.com. Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies. The agreement grants Novartis access to Chai Discovery’s latest AI models, including its Chai-3 model, to support antibody discovery efforts across a range of therapeutic…

Source: Pharmaceutical Technology